Moderna Reports Their Lower-Dose Covid-19 Vaccine Works In Babies and Young Children

KING 5

Adults and teens have had the opportunity to get vaccinated for Covid-19 for going on a year now; but the youngest population currently does not have the opportunity to get vaccinated against the virus.

While Covid doesn’t seem to have the same negative side effects on young children as it does on the older population, many parents still want to get their children vaccinated. We heard parents call it a “relief” when they were able to vaccinate their elementary school aged children, but many parents are still waiting not so patiently for a vaccine to be approved for their babies and pre-school aged children.

Moderna thinks they have the solution. The company is excited to report positive results of their KidCOVE study that included children from the ages of 6 months through 6 years of age.

Stéphane Bancel, the Chief Executive Officer of Moderna, explained, “We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age. We now have clinical data on the performance of our vaccine from infants six months of age through older adults. Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible. Additionally, after consultation with the U.S. FDA we have initiated a submission for emergency use authorization of our COVID-19 vaccine in children ages 6 to 11 years old and are updating our submission to the FDA for emergency use authorization of mRNA-1273 in adolescents ages 12 to 17 years with additional follow-up data. We remain committed to helping to end the COVID-19 pandemic with a vaccine for children of all ages.”

Watch the video below for more about this breaking news including when the vaccine for young children might become available.

There were approximately 11,700 babies and children that participated in Moderna’s KidCove study in the U.S. and Canada. During the study, participants were given the vaccine or a placebo. There are two doses, and they were administered 28 days apart.